Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. 2007

Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
Department of Gastroenterology, Chia-Yi Chang Gung Memorial Hospital and Chang Gung University, Chia-Yi, Taiwan.

BACKGROUND After endoscopic treatment of bleeding peptic ulcer, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding. The role of oral proton pump inhibitors for these patients is uncertain. The purpose of the present study was to assess whether the use of oral esomeprazole would reduce the frequency of recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. METHODS Patients with actively bleeding ulcers or ulcers with non-bleeding visible vessels were treated with an epinephrine injection followed by thermocoagulation. After hemostasis had been achieved, they were randomly assigned in a double-blind fashion to receive esomeprazole (40 mg p.o. twice daily for 3 days) or placebo. The outcome measures studied were recurrent bleeding, blood transfusion requirement, surgery and death. RESULTS A total of 70 patients were enrolled, 35 in each group. Bleeding recurred within 30 days in two patients (5.7%) in the esomeprazole group, as compared with three (8.6%) in the placebo group (P = 0.999). Blood transfusion requirement was 2.8 +/- 1.4 units in the esomeprazole group and 2.7 +/- 1.3 units in the placebo group (P = 0.761). Duration of hospitalization was 4.82 +/- 1.8 days in the esomeprazole group and 4.58 +/- 2.7 days in the placebo group (P = 0.792). No patients needed surgery for control of bleeding and no patients died in both groups. CONCLUSIONS After successful endoscopic treatment of bleeding peptic ulcer, oral use of esomeprazole might offer no additional benefit on the risk of recurrent bleeding.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010438 Peptic Ulcer Hemorrhage Bleeding from a PEPTIC ULCER that can be located in any segment of the GASTROINTESTINAL TRACT. Hemorrhage, Peptic Ulcer,Peptic Ulcer Hemorrhages,Ulcer Hemorrhage, Peptic
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer

Related Publications

Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
January 2012, Gastroenterology research and practice,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
August 2000, The New England journal of medicine,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
July 2001, Gastrointestinal endoscopy,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
July 2014, The American journal of gastroenterology,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
June 2005, Alimentary pharmacology & therapeutics,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
October 1981, The New England journal of medicine,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
January 1989, World journal of surgery,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
November 2001, Gut,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
January 2009, Scandinavian journal of gastroenterology,
Kou-Liang Wei, and Shui-Yi Tung, and Cheng-Han Sheen, and Te-Shen Chang, and I-Lin Lee, and Cheng-Shyong Wu
January 2009, Scandinavian journal of gastroenterology,
Copied contents to your clipboard!